• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    bioAffinity Technologies, Inc. - Warrant (NQ:BIAFW)

    0.3300 +0.0900 (+37.50%)
    Streaming Delayed Price Updated: 12:56 PM EDT, Mar 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 927
    Open 0.3900
    Bid (Size) 0.2601 (800)
    Ask (Size) 0.3300 (1,000)
    Prev. Close 0.2400
    Today's Range 0.3051 - 0.3900
    52wk Range 0.0525 - 0.8121
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic
    From bioAffinity Technologies, Inc.
    Via Business Wire

    Performance

    YTD
    +28.5%
    +28.5%
    1 Month
    +46.1%
    +46.1%
    3 Month
    -10.8%
    -10.8%
    6 Month
    +266.7%
    +266.7%
    1 Year
    -2.6%
    -2.6%

    More News

    Read More
    News headline image
    bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports Third Quarter 2025 Financial Results
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
    From bioAffinity Technologies
    Via Business Wire
    News headline image
    bioAffinity Technologies Appoints New Members to Board of Directors
    From bioAffinity Technologies, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is bioAffinity Technologies, Inc. - Warrant publicly traded?
    Yes, bioAffinity Technologies, Inc. - Warrant is publicly traded.
    What exchange does bioAffinity Technologies, Inc. - Warrant trade on?
    bioAffinity Technologies, Inc. - Warrant trades on the Nasdaq Stock Market
    What is the ticker symbol for bioAffinity Technologies, Inc. - Warrant?
    The ticker symbol for bioAffinity Technologies, Inc. - Warrant is BIAFW on the Nasdaq Stock Market
    What is the current price of bioAffinity Technologies, Inc. - Warrant?
    The current price of bioAffinity Technologies, Inc. - Warrant is 0.3300
    When was bioAffinity Technologies, Inc. - Warrant last traded?
    The last trade of bioAffinity Technologies, Inc. - Warrant was at 03/13/26 12:56 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.